Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Children's Hospital of Philadelphia
CRISPR Therapeutics
AvenCell Therapeutics, Inc.
Takeda
Vironexis Biotherapeutics Inc.
City of Hope Medical Center
Syndax Pharmaceuticals
Allogene Therapeutics
University of Chicago
Penn State University
Ossium Health, Inc.
City of Hope Medical Center
Celgene
Seattle Children's Hospital
Essen Biotech
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Incyte Corporation
Memorial Sloan Kettering Cancer Center